Bergamaschi Luca, Marvaso Giulia, Zaffaroni Mattia, Vincini Maria Giulia, D'Ecclesiis Oriana, Volpe Stefania, Ferrari Annamaria, Zorzi Stefano Filippo, Rocca Maria Cossu, Sabbatini Annarita, Cannillo Giulia, Zagallo Emanuela, Starzyńska Anna, Ansarin Mohssen, Cattani Federica, Gandini Sara, Orecchia Roberto, Alterio Daniela, Jereczek-Fossa Barbara Alicja
Division of Radiation Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Cancers (Basel). 2023 Jan 24;15(3):723. doi: 10.3390/cancers15030723.
The current study aims to profile sarcopenic condition (both at baseline and developed during treatment) in oropharyngeal carcinoma (OPC) patients treated with curative radiotherapy (RT) +/- chemotherapy and to evaluate its impact on oncological outcomes and toxicity. A total of 116 patients were included in this retrospective single-center study. Sarcopenia assessment at baseline and at 50 Gy re-evaluation CT was obtained from two different methodologies: (i) the L3-skeletal muscle index (SMI) derived from the contouring of the cross-sectional area (CSA) of the masticatory muscles (CSA-MM); and (ii) the paravertebral and sternocleidomastoid muscles at the level of the third cervical vertebra (CSA-C3). Based on L3-SMI from CSA-MM, developing sarcopenic condition during RT (on-RT sarcopenia) was associated with worse progression-free survival (PFS) ( = 0.03) on multivariable analysis and a trend of correlation with overall survival (OS) was also evident ( = 0.05). According to L3-SMI derived from CSA-C3, on-RT sarcopenia was associated with worse PFS ( = 0.0096) and OS ( = 0.013) on univariate analysis; these associations were not confirmed on multivariable analysis. A significant association was reported between becoming on-RT sarcopenia and low baseline haemoglobin ( = 0.03) and the activation of nutritional counselling ( = 0.02). No significant associations were found between sarcopenia and worse RT toxicity. Our data suggest that the implementation of prompt nutritional support to prevent the onset of sarcopenia during RT could improve oncological outcomes in OPC setting.
本研究旨在剖析接受根治性放疗(RT)±化疗的口咽癌(OPC)患者的肌肉减少症情况(包括基线时以及治疗期间出现的情况),并评估其对肿瘤学结局和毒性的影响。本项回顾性单中心研究共纳入116例患者。通过两种不同方法获得基线时和50 Gy重新评估CT时的肌肉减少症评估结果:(i)咀嚼肌横截面积(CSA-MM)轮廓得出的L3骨骼肌指数(SMI);(ii)第三颈椎水平的椎旁肌和胸锁乳突肌(CSA-C3)。基于CSA-MM的L3-SMI,放疗期间出现肌肉减少症情况(放疗期间肌肉减少症)在多变量分析中与无进展生存期(PFS)较差相关(P = 0.03),与总生存期(OS)的相关性趋势也很明显(P = 0.05)。根据CSA-C3得出的L3-SMI,放疗期间肌肉减少症在单变量分析中与较差的PFS(P = 0.0096)和OS(P = 0.013)相关;多变量分析未证实这些相关性。放疗期间出现肌肉减少症与低基线血红蛋白(P = 0.03)和营养咨询启动(P = 0.02)之间存在显著关联。未发现肌肉减少症与更严重的放疗毒性之间存在显著关联。我们的数据表明,在放疗期间实施及时的营养支持以预防肌肉减少症发作,可能会改善OPC患者的肿瘤学结局。